Application of 14-3-3 sigma in colon cancer treatment

The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched,...

Full description

Saved in:
Bibliographic Details
Main Authors YANG RUNXIANG, LIU SICHENG, LI MENGHONG
Format Patent
LanguageChinese
English
Published 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched, and the condition that the 14-3-3 sigma regulates hypoxia-mediated colon cancer metastasis and angiogenesis by regulating HIF-1alpha and promotes the drug sensitivity of bevacizumab is further clarified; mechanism research proves that 14-3-3 sigma and E3 ubiquitin ligase NEDD4L are combined to form a protein complex to regulate and control signal transduction of HIF-1alpha ubiquitination proteasome degradation, and finally the value of combined expression of 14-3-3 sigma and HIF-1alpha in the aspect of colon cancer prognosis is proved. 本发明公开了一种14-3-3σ在结肠癌治疗中的应用。本发明从促进结肠癌转移与血管生成的乏氧肿瘤微环境入手,探究适应性蛋白14-3-3σ与结肠癌转移和预后之间的联系,进一步阐明14-3-3σ通过调控HIF-1α来调节乏氧介导的结肠癌转移与血管生成并促进贝伐珠单抗的药物敏感性,机制研究证实14-3-3σ与E3泛素连接酶NEDD4L结合形成蛋白复合体调控HIF-1α
AbstractList The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched, and the condition that the 14-3-3 sigma regulates hypoxia-mediated colon cancer metastasis and angiogenesis by regulating HIF-1alpha and promotes the drug sensitivity of bevacizumab is further clarified; mechanism research proves that 14-3-3 sigma and E3 ubiquitin ligase NEDD4L are combined to form a protein complex to regulate and control signal transduction of HIF-1alpha ubiquitination proteasome degradation, and finally the value of combined expression of 14-3-3 sigma and HIF-1alpha in the aspect of colon cancer prognosis is proved. 本发明公开了一种14-3-3σ在结肠癌治疗中的应用。本发明从促进结肠癌转移与血管生成的乏氧肿瘤微环境入手,探究适应性蛋白14-3-3σ与结肠癌转移和预后之间的联系,进一步阐明14-3-3σ通过调控HIF-1α来调节乏氧介导的结肠癌转移与血管生成并促进贝伐珠单抗的药物敏感性,机制研究证实14-3-3σ与E3泛素连接酶NEDD4L结合形成蛋白复合体调控HIF-1α
Author YANG RUNXIANG
LI MENGHONG
LIU SICHENG
Author_xml – fullname: YANG RUNXIANG
– fullname: LIU SICHENG
– fullname: LI MENGHONG
BookMark eNrjYmDJy89L5WQwdSwoyMlMTizJzM9TyE9TMDTRNdY1VijOTM9NVMjMU0jOzwFKJCfmJacWKZQUpSaW5KbmlfAwsKYl5hSn8kJpbgZFN9cQZw_d1IL8-NTigsTk1LzUknhnP0NDc0MTEwMDE0djYtQAAKttLVc
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Physics
DocumentTitleAlternate 14-3-3σ在结肠癌治疗中的应用
ExternalDocumentID CN117144004A
GroupedDBID EVB
ID FETCH-epo_espacenet_CN117144004A3
IEDL.DBID EVB
IngestDate Fri Sep 06 06:15:39 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CN117144004A3
Notes Application Number: CN202310903224
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231201&DB=EPODOC&CC=CN&NR=117144004A
ParticipantIDs epo_espacenet_CN117144004A
PublicationCentury 2000
PublicationDate 20231201
PublicationDateYYYYMMDD 2023-12-01
PublicationDate_xml – month: 12
  year: 2023
  text: 20231201
  day: 01
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies THE SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY
RelatedCompanies_xml – name: THE SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY
Score 3.6431262
Snippet The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer...
SourceID epo
SourceType Open Access Repository
SubjectTerms BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
TESTING
VINEGAR
WINE
Title Application of 14-3-3 sigma in colon cancer treatment
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231201&DB=EPODOC&locale=&CC=CN&NR=117144004A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsTRNSUw2M0jVNTU1NtcFtm-BeS7ZxFg3ycwy2SwRiA3Ap-37-pl5hJp4RZhGMDFkwfbCgM8JLQcfjgjMUcnA_F4CLq8LEINYLuC1lcX6SZlAoXx7txBbFzVo7xjYWAFWaGouTrauAf4u_s5qzs62zn5qfkG2hqCLvkHp1ZGZgRXUjAads-8a5gTalVKAXKW4CTKwBQBNyysRYmCqyhBm4HSG3bwmzMDhC53wFmZgB6_QTC4GCkJzYbEIg6kjYtZZIT9NwdBE11jXWKE4Mz03USEzTwF0EDWQBMVnkQJ8Jbkog6Kba4izhy7QJfFwb8c7-yEcbSzGwJKXn5cqwaAAGgOwTDE3T00xBrZlkhOBQZ2YYphoZJRsaWKRkmgpySCF2xwpfJLSDFygIIQs1pBhYCkpKk2VBVa5JUly4LACAGMnguM
link.rule.ids 230,309,786,891,25594,76904
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsTRNSUw2M0jVNTU1NtcFtm-BeS7ZxFg3ycwy2SwRiA3Ap-37-pl5hJp4RZhGMDFkwfbCgM8JLQcfjgjMUcnA_F4CLq8LEINYLuC1lcX6SZlAoXx7txBbFzVo7xjYWAFWaGouTrauAf4u_s5qzs62zn5qfkG2hqCLvkHp1ZGZgdUc2CUEnbPvGuYE2pVSgFyluAkysAUATcsrEWJgqsoQZuB0ht28JszA4Qud8BZmYAev0EwuBgpCc2GxCIOpI2LWWSE_TcHQRNdY11ihODM9N1EhM08BdBA1kATFZ5ECfCW5KIOim2uIs4cu0CXxcG_HO_shHG0sxsCSl5-XKsGgABoDsEwxN09NMQa2ZZITgUGdmGKYaGSUbGlikZJoKckghdscKXyS8gycHiG-PvE-nn7e0gxcoOCELNyQYWApKSpNlQVWvyVJcuBwAwCofIXO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Application+of+14-3-3+sigma+in+colon+cancer+treatment&rft.inventor=YANG+RUNXIANG&rft.inventor=LIU+SICHENG&rft.inventor=LI+MENGHONG&rft.date=2023-12-01&rft.externalDBID=A&rft.externalDocID=CN117144004A